Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Ermium Therapeutics, a France-based autoimmune disease therapy developer leveraging Paris Descartes University and CNRS research, closed a €6.3m ($6.9m) series A round yesterday backed by regional tech transfer office Satt Erganeo, biopharmaceutical company Domain Therapeutics, Kurma Partners and Idinvest. Founded in June 2019, Ermium aims to develop immunomodulators targeting the chemokine receptor CXCR4 to treat…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.